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Background and purpose: There is still no curative treatment for multiple scle-
rosis (MS), but during the last 20 years eight diﬀerent disease-modifying com-
pounds have been approved for relapsingremitting MS (RRMS).
Methods: A literature search was conducted on published randomized con-
trolled phase III trials indexed in PubMed on the approved medications until
21 May 2015.
Results: In this review the mode of action, documented treatment eﬀects and
side eﬀects of the approved MS therapies are brieﬂy discussed.
Conclusions: Based on current knowledge of riskbeneﬁt of the approved MS
medications, including factors inﬂuencing adherence, it is suggested that oral
treatment with dimethyl fumarate or teriﬂunomide should be preferred as a
starting therapy amongst the ﬁrst-line preparations for de novo RRMS. In the
case of breakthrough disease on ﬁrst-line therapy, or rapidly evolving severe
RRMS, second-line therapy with natalizumab, ﬁngolimod or alemtuzumab
should be chosen based on careful riskbeneﬁt stratiﬁcation.
Introduction
Multiple sclerosis (MS) is a common cause of dis-
ability in young adults. Irreversible axonal damage
occurs even in the earliest phases of disease evolu-
tion [1]. Although some people with relapsingremit-
ting MS (RRMS) have a ‘benign’ disease course
with minimal disease activity and impairment, most
patients experience increasing disability over time
and eventually convert to secondary progressive MS
(SPMS). There is still no curative treatment, but
during the last 20 years eight diﬀerent therapies have
become available including interferon beta, glati-
ramer acetate, teriﬂunomide, dimethyl fumarate,
natalizumab, ﬁngolimod, alemtuzumab and mitox-
antrone, and several new compounds are in develop-
ment. All the approved medications have mainly
anti-inﬂammatory eﬀects and increasing evidence
indicates that all of them are more eﬀective in the
early phases of disease development [2,3]. With the
development of more eﬀective treatments, the aim of
treatment has changed dramatically in the last
decades, from simply reducing relapse rates and
slowing of disability progression to preventing all
evidence of new disease activity [4]. In the current
review, the mode of action and documented eﬀect of
the current immunomodulatory MS therapies are
brieﬂy discussed.
Methods
The article is based on English-language original clini-
cal treatment trials and selected review articles, identi-
ﬁed through a literature search in PubMed using the
search term ‘multiple sclerosis’ combined with ‘inter-
feron beta’, ‘glatiramer acetate’, ‘teriﬂunomide’,
‘dimethyl fumarate’, ‘natalizumab’, ‘ﬁngolimod’, ‘mi-
toxantrone’ and ‘alemtuzumab’. The search was termi-
nated on 21 May 2015. Titles and abstracts have been
reviewed, and full-text versions of articles examined in
the majority of cases. Particular emphasis has been
placed on randomized controlled phase III studies.
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First-line medications
Interferon beta
Interferon beta is a naturally occurring polypeptide
predominantly produced by ﬁbroblasts. Its anti-in-
ﬂammatory eﬀects are largely believed to result from
the inhibition of T-lymphocyte proliferation, a shift of
cytokine response from an inﬂammatory response to
an anti-inﬂammatory proﬁle, and reduced migration
of inﬂammatory cells across the blood–brain barrier
[5]. Interferon beta is available for MS treatment in
recombinant forms, as interferon beta-1a or interferon
beta-1b. Interferon beta-1b is given as a dose of
250 lg subcutaneously every other day; interferon
beta-1a is given as a dose of 30 lg intramuscularly
once weekly or subcutaneously at doses of 22 or
44 lg three times a week.
Phase III trials of all the interferon beta preparations
have shown beneﬁcial eﬀects in reducing the annual-
ized relapse rate (ARR) by about 30%–34%, reducing
the progression of disability in RRMS as well as mag-
netic resonance imaging (MRI) disease activity [6–9]. A
recent study on peginterferon beta-1a, given once every
2 weeks, found comparable results, with a reduction in
ARR at 36% [10]. Studies of all interferon beta prepa-
rations [11–14] have also reported a reduced risk of
new disease activity amongst people with clinically iso-
lated syndrome (CIS), as shown by a signiﬁcantly pro-
longed time to a second relapse and reduction in new
MRI lesions, in some cases also a delayed progression
of disability. All the interferon beta preparations have
been evaluated in the treatment of SPMS. The ﬁrst
interferon beta-1b study showed eﬃcacy of the treat-
ment as measured by both relapse rate and disability
progression [15], but later studies of both interferon
beta-1b and interferon beta-1a could only detect treat-
ment eﬀects on the relapse rate [16–18]. Thus, it seems
that only SPMS patients with superimposed relapses
beneﬁt from interferon beta treatment [15–18]. Interfer-
ons have not been documented to be eﬀective in pri-
mary progressive MS (PPMS) [19].
Most patients (50%–75%) experience ﬂu-like symp-
toms, including muscle aches, fever, chills, headache
and back pain, that usually appear 2–8 h after an
injection and resolve within 24 h. Liver enzymes may
be elevated and bone marrow function may be
depressed, which warrants periodic surveillance of
liver function and blood counts before starting ther-
apy and every 6 months thereafter [11–14]. Isolated
cases of severe injection-site reactions involving infec-
tion or necrosis as well as severe cases of acute liver
failure and pancreatitis have been reported. Long-time
exposure to interferon beta does not seem to increase
the risk of cancer [20,21] or infections.
Interferon beta treatment may induce formation of
speciﬁc neutralizing antibodies (NABs). NAB forma-
tion is less likely during treatment with intramuscular
interferon beta-1a [22]. The NABs usually appear
within 6–18 months of treatment, and evidence is
accumulating that the eﬃcacy of treatment is reduced
in the presence of NABs. Accordingly, it is recom-
mended to test all patients for the presence of NABs
every 6 months during the ﬁrst 2 years of therapy,
and treatment should be switched in patients who are
conﬁrmed to be NAB positive [22]. In cases of clini-
cally stable disease, switches to other non-interferon
ﬁrst-line treatments are recommended, but second-line
treatment should be considered in cases of break-
through disease.
Glatiramer acetate
Glatiramer acetate is a pool of synthetic peptides,
resembling sequences of myelin basic protein, with an
average length of 40–100 residues. The mechanisms of
action have not been fully clariﬁed but are probably lar-
gely related to anti-inﬂammatory eﬀects by promoting
Th2 deviation under the development of Th2 glatiramer
acetate reactive CD4+ T cells. These can accumulate in
the central nervous system (CNS) and promote bystan-
der suppression by releasing anti-inﬂammatory cytoki-
nes [23]. Glatiramer acetate is administered as
subcutaneous injections of 20 mg once a day.
Glatiramer acetate treatment trials in RRMS [24]
showed a signiﬁcant reduction in ARR (29%) and a
reduction in gadolinium-enhanced MRI activity [25].
In a treatment trial of CIS with silent MRI lesions,
glatiramer acetate treatment was found to signiﬁcantly
prolong time to a second relapse and to reduce the
risk of new MRI lesions [26]. Glatiramer acetate has
not been investigated for the treatment of SPMS and
has not shown signiﬁcant beneﬁt in PPMS patients
[27].
Glatiramer acetate is usually well tolerated, but
most patients (65%) experience injection-site reactions
(pain, erythema, swelling and pruritus). About 15%
report a transient self-limited systemic reaction (imme-
diately after injection) of facial ﬂushing and chest
tightness, accompanied at times by palpitation, anxi-
ety and dyspnoea. Other reported side eﬀects are lym-
phadenopathy, dyspnoea and lipoatrophy [24–26].
Lipoatrophy is permanent and is perhaps the most
severe side eﬀect. There have not been reports of
increased cancer risk or increased risk of infections
with prolonged use of glatiramer acetate.
Teriflunomide
Teriﬂunomide is an immunomodulatory agent that
selectively and reversibly inhibits the mitochondrial
© 2015 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
DISEASE-MODIFYING TREATMENTS FOR MS 19
enzyme dihydroorotate dehydrogenase, required for
de novo pyrimidine synthesis. This leads to reduced
proliferation of dividing cells that need de novo syn-
thesis of pyrimidine to expand. The therapeutic eﬀect
in MS is not fully understood but it is probably medi-
ated by a reduced number of circulating lymphocytes
[28]. Teriﬂunomide is administered as tablets, 14 mg
once daily.
Two phase III trials in RRMS [29,30] showed that
teriﬂunomide 14 mg once daily, compared to placebo,
reduced the ARR by 31%–36%, the rate of disability
progression by 26%–27% and MRI gadolinium-
enhancing lesions by about 80%. Another phase III
trial of teriﬂunomide 14 mg once daily, compared to
interferon beta-1a 44 lg subcutaneously three times
weekly, showed similar eﬀects on the ARR (0.26 and
0.22 respectively) and on time to a new relapse or ter-
mination of treatment [31]. Teriﬂunomide 14 mg once
daily has been tested in a randomized, double-blind,
placebo-controlled trial of CIS patients with silent
MRI lesions. Teriﬂunomide treatment was associated
with signiﬁcantly prolonged time to a second relapse
and a reduction in new MRI lesions [32]. Teriﬂuno-
mide has not been studied for the treatment of pro-
gressive MS.
Common adverse events include upper respiratory
tract infection, urinary tract infection, paraesthesia,
diarrhoea, nausea, hair thinning, alanine aminotrans-
ferase increase, reduction in blood leucocytes and
increase in blood pressure [29,30]. Relatively frequent
(every second week) alanine aminotransferase screening
during the ﬁrst 6 months of treatment is recommended
and thereafter every second month [29,30]. Teriﬂuno-
mide treatment should be stopped if liver transaminase
levels increase three times above upper normal levels.
Regular measurements of blood pressure, white blood
cells and platelet counts are also recommended. Teri-
ﬂunomide has a long half-life. Elimination with
cholestyramine or activated charcoal for 11 days can
accelerate teriﬂunomide elimination, leading to more
than 98% decrease in teriﬂunomide plasma concentra-
tions. Liver function needs to be carefully monitored
during teriﬂunomide treatment, and discontinuation of
therapy should be considered if a serum transaminase
increase more than three times the upper normal level
is conﬁrmed. Rare cases of pancytopenia have been
reported with the use of leﬂunomide; this should also
lead to treatment termination.
Dimethyl fumarate
Dimethyl fumarate is an immunomodulatory agent
with anti-inﬂammatory properties, but the mechanism
of action in MS is only partially understood. Pre-clini-
cal studies indicate that dimethyl fumarate responses
are primarily mediated through activation of the
nuclear factor (erythroid-derived 2)-like 2 (Nrf2) tran-
scriptional pathway. Dimethyl fumarate has also been
shown to upregulate Nrf2-dependent antioxidant
genes in patients [33]. Dimethyl fumarate is adminis-
tered as a 240 mg capsule twice daily.
Two phase III trials of RRMS [34,35] showed that
dimethyl fumarate 240 mg twice daily, compared to
placebo, reduced the ARR by 44%–53%, the rate of
disability progression by 22%–32% and MRI gadolin-
ium-enhancing lesions by about 75%–94%. Compared
to glatiramer acetate as an active comparator in one
of the trials [35], dimethyl fumarate 240 mg twice
daily reduced the ARR by 24% and the rate of dis-
ability progression by 17%. These diﬀerences were
not signiﬁcant and the study was not powered to
detect statistically signiﬁcant diﬀerences in treatment
eﬀect. The number of new and enlarging MRI T2
lesions was signiﬁcantly reduced by about 36%.
Dimethyl fumarate has not been studied for the treat-
ment of CIS or progressive MS.
Common adverse events include ﬂushing, nausea,
diarrhoea and abdominal pain [34,35]. The treatment
may also reduce white blood cell counts and give ele-
vations of hepatic transaminases; regular blood tests
are therefore recommended [34,35]. Dimethyl fuma-
rate should be stopped if liver transaminase levels
increase three times above upper normal levels.
Recently, a case of John Cunningham virus (JCV)
induced progressive multifocal leucoencephalopathy
(PML) was reported in a patient who had received
dimethyl fumarate [36]. An additional four PML cases
have been previously reported in psoriasis patients
who had received fumaderm [37]. Prolonged severe
lymphopaenia (<500 cells per cubic millimetre) that
persists for more than 6 months has been suggested as
a risk factor for PML. In the case of persistent lym-
phopaenia, dimethyl fumarate should be terminated in
JCV-positive patients.
Second-line medications
Fingolimod
Fingolimod is an oral sphingosine 1-phosphate recep-
tor (S1PR) modulator that subsequent to its phospho-
rylation binds with high aﬃnity to S1PR, which in
turn leads to an internalization and degradation of
the receptor in diﬀerent tissues and cell types, includ-
ing lymphocytes. As a consequence, ﬁngolimod inhi-
bits the ability of autoreactive lymphocytes to egress
from the lymph nodes towards the CNS. Fingolimod
0.5 mg capsules are given orally once daily [38].
Two phase III trials in RRMS [38,39] showed that
ﬁngolimod 0.5 mg once daily, compared to placebo,
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reduced the ARR by 48%–55%, the rate of disability
progression by 25%–30% and MRI gadolinium-en-
hancing lesions by more than 80%. Another study
comparing ﬁngolimod 0.5 mg once daily to interferon
beta-1a 30 lg intramuscularly once weekly showed a
reduced ARR by 52%, a reduced rate of disability
progression by 25% and a reduced number of MRI
gadolinium-enhancing lesions by more than 50%
amongst those who received ﬁngolimod [40]. Fin-
golimod is currently not documented to be eﬀective
against CIS, SPMS or PPMS.
Common adverse events include upper respiratory
tract infection, headache, cough, diarrhoea and back
pain [38,39]. Fingolimod may also cause a transient
bradycardia and atrioventricular block. It is therefore
recommended to monitor patients continuously with
an electrocardiogram for 6 h after the ﬁrst dose, and
to extend the monitoring of patients who develop
speciﬁc clinically relevant signs of heart arrhythmia
(http://www.fda.gov/Drugs/DrugSafety/
ucm303192.htm). Generally, ﬁngolimod should not be
used by patients with known cardiac arrhythmias or
patients using other medications known to induce
bradycardia. Rare adverse events of elevated liver
enzymes and macular oedema may occur, and regular
blood sampling and a routine eye examination after
3 months of treatment are therefore recommended.
One death due to a fulminant primary varicella zoster
infection was reported in one of the phase III trials
[40]. Therefore a blood sample for screening of previ-
ous varicella zoster infection is advised, and in the
case of a negative screening test vaccination is recom-
mended prior to treatment initiation.
Natalizumab
Natalizumab is a monoclonal antibody against a4-in-
tegrin, blocking the interaction with its ligands. The
mechanism of action is largely through preventing
adherence of activated leucocytes to inﬂamed endothe-
lium, thus inhibiting the migration of inﬂammatory
cells into the CNS. Natalizumab is administered as a
300 mg intravenous infusion every 4 weeks [41].
The pivotal phase III trial of RRMS showed that
natalizumab monotherapy reduced the ARR by 68%,
the rate of disability progression by 54% and MRI
gadolinium-enhancing lesions by more than 90% com-
pared to placebo [41]. Another study [42] found that
treatment with natalizumab added to interferon beta-1a
was signiﬁcantly more eﬀective than interferon beta-1a
alone in reducing ARR, new T2 lesions and disability
progression. Natalizumab is currently not documented
to be eﬀective against CIS, SPMS or PPMS.
Although natalizumab is generally well tolerated,
the treatment is associated with an increased risk of
developing PML [43]. This is a potentially life-threat-
ening CNS infection of oligodendrocytes by the JCV.
Therefore all patients receiving natalizumab should be
screened for previous JCV infection. The risk for
PML in JCV-negative patients is low (<0.09/1000) and
is probably associated with recent seroconversion (es-
timated as 2%–3% each year) or a false negative test.
Amongst the JCV-positive patients the risk of devel-
oping PML is inﬂuenced by treatment duration and
previous immunosuppressive treatment. The risk is
relatively low during the ﬁrst 2 years of treatment and
increases thereafter. The highest risk is found amongst
JCV-positive patients who previously have also
received immunosuppressive treatment after 2 years of
treatment (~1/60) [44]. Anti-JCV antibody levels seem
also to diﬀerentiate PML risk in anti-JCV antibody
positive patients with no prior immunosuppressant
use [45]. As a general rule, it is recommended that
JCV-positive patients who have been treated with
natalizumab for more than 2 years should be switched
to another second-line therapy. Based on current
knowledge, a washout time of 8 weeks seems to
reduce the risk of rebound eﬀect compared to longer
washout periods. In the case of a low JCV index
(<1.5), natalizumab treatment may in some cases be
continued after thorough information is given to the
patient and under careful evaluation for new symp-
toms that may represent PML [44]. Three-monthly
JCV index evaluation and MR examination is then
recommended. It is recommended to retest JCV-nega-
tive patients every 6 months and JCV-positive patients
should be carefully informed about the risk for PML
at treatment initiation and after 2 years of treatment.
Natalizumab treatment may induce an immune
response, with the formation of persistent NABs
(~4%–6%) against the preparation. NABs usually
appear within the ﬁrst 12 months of treatment, reduce
the eﬃcacy of the treatment and are associated with
higher rates of infusion-related adverse events.
Accordingly, patients should be tested for NABs at 6
and 12 months of therapy and later for infusion-re-
lated adverse events or treatment failure. NABs can
occur transiently and positive ﬁndings should there-
fore be conﬁrmed within 3 months before deciding to
switch therapy. Testing can be discontinued in
patients who remain NAB negative during the ﬁrst
year of therapy.
Alemtuzumab
Alemtuzumab is a recombinant, humanized mono-
clonal antibody directed against CD52, a cell surface
antigen present at high levels on especially T and B
lymphocytes. Alemtuzumab acts through antibody-
dependent cellular cytolysis and complement-mediated
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lysis following cell surface binding. The mechanism by
which alemtuzumab exerts its therapeutic eﬀects in
MS is suggested to be by a depletion and repopulation
of lymphocytes that reduces the potential for relapses
and thereby delays disease progression [46]. Alem-
tuzumab is administered by intravenous infusion for
two treatment courses. The initial treatment course is
12 mg/day for ﬁve consecutive days (60 mg total
dose), and the second treatment course is 12 mg/day
for three consecutive days (36 mg total dose) adminis-
tered 12 months after the initial treatment course.
Additional courses may be given 12 months after the
latest treatment course if necessary. Based on the
European Medicines Agency (EMA) licence alem-
tuzumab has indication as a ﬁrst-line medication in
active RRMS. Because the treatment increases the risk
of secondary autoimmunity, most European neurolo-
gists would use this drug as a second-line preparation,
however.
Two phase III trials of RRMS have shown that
alemtuzumab 12, compared to interferon beta-1a
44 lg administered subcutaneously three times weekly,
reduced the ARR by 49%–55%, the rate of disability
progression by 30%–42% and MRI gadolinium-
enhancing lesions by 61%–63% [47,48]. Alemtuzumab
has currently not been studied in patients with CIS or
PPMS and has not been demonstrated to be eﬀective
in SPMS [49,50].
Patients commonly experience infusion-associated
reactions including ﬂushing, nausea, headache, tachy-
cardia, urticaria, rash, pruritus, pyrexia and fatigue
[47–50]. Oral antiviral prophylaxis with aciclovir
200 mg twice daily (or equivalent) should be adminis-
tered and continued for a minimum of 1 month after
the last dose. Alemtuzumab treatment is associated
with increased risk of upper respiratory tract infection
and urinary tract infection. Alemtuzumab treatment
may also result in the formation of autoantibodies
and increased risk of autoimmune-mediated condi-
tions (occurring a median of 32 months after the ﬁrst
treatment), including thyroid disorders (41%),
immune thrombocytopenic purpura (3.5%) or, rarely,
nephropathies (e.g. anti-glomerular basement mem-
brane disease) (<1%) [51]. Based on the risk of
autoimmune-mediated conditions, monthly blood and
urine analyses are recommended for 4 years after the
last dosing of alemtuzumab.
Mitoxantrone
Mitoxantrone is a synthetic anthracenedione deriva-
tive and is mostly used in treating various malignan-
cies. It interacts with nuclear DNA and is a potent
immunosuppressive agent targeting proliferating
immune cells, inhibiting proliferation and inducing
apoptosis of T lymphocytes, B lymphocytes, macro-
phages and other antigen-presenting cells.
Limited eﬃcacy data are available, but controlled
studies of highly active RRMS have shown signiﬁcant
eﬃcacy of the treatment, as shown by a 60%–70%
reduction in the relapse rate (compared with placebo
or intravenous methylprednisolone) as well as reduced
disability progression and MRI disease activity
[52,53]. The largest phase III investigator-blinded
study randomized patients with worsening RRMS and
SPMS for 5 or 12 mg of mitoxantrone per square
metre of body surface or placebo every 3 months for
2 years [54]. The treatment showed a 66% reduction
in the ARR in the high-dose arm compared with pla-
cebo, and reduced disability progression and MRI dis-
ease activity. Mitoxantrone has not been included in
treatment trials of patients with CIS or PPMS.
Side eﬀects such as transient nausea, fatigue, mild
hair loss (for days to a week) and menstrual distur-
bances are frequent (60%–70%) [54]. Additional side
eﬀects are urinary tract infection (about 30%) as well
as elevated liver enzymes and leucopenia (about 15%–
20%). Mitoxantrone-induced amenorrhoea and acute
promyelocytic leukaemia have also been reported. The
treatment induces transient leucopenia, with a nadir
after about 10 days, and thus follow-up blood control
is needed. Although not in the phase III trial, lethal
congestive heart failure and therapy-related leukaemia
have been reported, even years after treatment ends
[55,56]. Due to the potential cardiotoxicity, the maxi-
mum cumulative dose is restricted to 120–140 mg/m2
of body surface, and echocardiograms should be done
before, during and after treatment. Mitoxantrone is
teratogenic and is absolutely contraindicated in preg-
nancy. The use of mitoxantrone has rapidly decreased
due to the risk of severe complications and the
increasing number of alternative highly eﬀective and
less toxic treatment options.
Suggested treatment strategies
Individualized therapy is advocated; the ideal treat-
ment option would be the safest treatment that elimi-
nates clinical and radiological evidence of disease
activity [3]. Most patients would start on a ﬁrst-line
therapy but then be changed quickly to a second-line
medication in the case of breakthrough disease activ-
ity (Fig. 1). Evidence of clinical disease activity (re-
lapses and/or accumulating disability) with or without
new MRI lesions is in general accepted as an indica-
tion for switching to more potent second-line thera-
pies. In this context, models like the Rio or modiﬁed
Rio score [57] have been increasingly accepted as a
tool to monitor the treatment eﬀect. The score is
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based on evaluation of treatment response by the
combination of clinical (relapse and disability progres-
sion) and MRI disease activity (Rio score) or relapse
and MRI disease activity only (modiﬁed Rio score)
during the ﬁrst year of interferon treatment. Increas-
ing evidence indicates that patients experiencing a new
clinical relapse with signiﬁcant inﬂuence on disability
and/or new signs of radiological disease activity (≥3
active MRI lesions) during the last year, whilst on
ﬁrst-line medications, should be considered for switch-
ing to more potent medications [58,59].
Another possible treatment strategy is induction
treatment, which consists of early use of immunosup-
pressive medications followed by long-term mainte-
nance therapy [60]. This treatment regime has been
used with success for patients with aggressive RRMS,
using mitoxantrone [61]. The use of mitoxantrone is
declining because of its long-term safety proﬁle. Alem-
tuzumab is approved as a ﬁrst-line therapy, and could
also be considered an induction treatment because of
its long-term eﬀects on the immune system. This could
be an attractive treatment option for patients with a
highly active disease course, as 70.1% of the alem-
tuzumab-treated patients in the CARE-MS study
remained free of new lesions and MRI activity in year
4, despite most receiving their last treatment course
3 years prior [62].
Choosing amongst the first-line medications
The main ﬁndings from the pivotal and phase III
studies performed are given in Tables 1 and 2.
Although the placebo-controlled trials indicate numer-
ically higher eﬃcacy on ARR from dimethyl fumarate
(about 44%–53%) compared to the other ﬁrst-line
preparations (about 30%–35%), data on direct com-
parisons of the agents are limited. Head-to-head com-
parison between dimethyl fumarate and glatiramer
acetate indicated numerically (although not statistically
signiﬁcant) better eﬀect from dimethyl fumarate [35].
Head-to-head comparison between teriﬂunomide and
high-frequency interferon beta-1a showed comparable
eﬀects on the ARR [29]. Head-to-head comparisons
between intramuscular low-dose and low-frequency
interferon beta-1a and subcutaneous high-dose and
high-frequency interferon beta-1a and interferon beta-
1b have shown that high-dose and high-frequency
interferon beta regimens have short-term beneﬁts on
the relapse rate and MRI activity [63,64]. Limitations
in the design of these studies have been widely dis-
cussed, however, and the long-term diﬀerences in
eﬃcacy may be reduced by a signiﬁcantly lower
frequency of NAB formation with low-dose and low-
frequency interferon beta-1a. Head-to-head compar-
isons of glatiramer acetate and subcutaneous high-dose
and high-frequency interferon beta-1a and interferon
beta-1b have shown similar clinical beneﬁt from the
treatments, with some MRI parameters in favour of
the interferon beta preparations [65,66].
Disease-modifying treatment for MS is a long-last-
ing therapy for most patients. Adherence to treatment
is thus crucial, and many patients may therefore pre-
fer oral treatment. Consequently starting with an oral
ﬁrst-line drug is suggested. In the case of intolerability
or unacceptable side eﬀects, switching between the
oral preparations or with one of the injectable prepa-
rations should be considered. The injectable medica-
tions have been used for a longer period than the oral
medications, and more long-term safety data are
therefore available [20,21]. Similarly, there are more
long-term safety data on pregnancies occurring during
treatments with both glatiramer acetate and interfer-
ons, pointing to a relative safety of use [67]. These
could be good reasons for still choosing an injectable
medication as ﬁrst-line treatment. It is important to
Figure 1 Treatment algorithm for treatment-na€ıve patients with RRMS. *Patients with rapidly evolving severe RRMS should start
directly on a second-line therapy. Breakthrough disease activity is deﬁned as one new clinical relapse with signiﬁcant inﬂuence on dis-
ability and/or new signs of radiological disease activity (≥3 active MRI lesions) during the last year whilst on ﬁrst-line medication.
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continuously evaluate the treatment regimen, aiming
for optimal adherence, considering both the adminis-
tration form and side-eﬀect proﬁles.
Choosing amongst the second-line medications
In the case of breakthrough disease activity despite a
full and adequate course of a ﬁrst-line preparation,
switching to natalizumab, ﬁngolimod or alemtuzumab
should be considered. Although alemtuzumab is
licensed as a ﬁrst-line medication in active RRMS,
many European neurologists would use this drug as a
second-line preparation, due to potential side eﬀects.
Second-line therapy should also be considered in the
case of patients with rapidly evolving severe RRMS
Table 1 Randomized placebo-controlled phase III clinical trials of the approved relapsingremitting multiple sclerosis medications
Medication N
Trial name
(reference)
ARR Disability progression
Relative
reduction ARR
Relative
reduction
EDSS
progression
First-line
Interferon beta-1b 124 vs. 123 MSSG [6] 34% 0.84 vs. 1.27 29% (N.S.) 0.20 vs. 0.28
Interferon beta-1a i.m. 158 vs. 143 MSCRG [7] 18% 0.67 vs. 0.82 37% 0.22a vs. 0.35a
Interferon beta-1a s.c. 184 vs. 187 PRISMS [8] 32% 1.73 vs. 2.56 32% 0.26 vs. 0.38
Peginterferon-1a 500 vs. 512 ADVANCE [10] 36% 0.26 vs. 0.40 36% 0.07 vs. 0.11
Glatiramer acetate 125 vs. 126 CMSSG [24] 29% 1.19 vs. 1.68 12% (N.S.) 0.22 vs. 0.25
Teriﬂunomide 358 vs. 363 TEMSO [29] 31% 0.37 vs. 0.54 26% 0.20 vs. 0.27
Teriﬂunomide 370 vs. 388 TOWER [30] 36% 0.32 vs. 0.50 24% 0.16 vs. 0.21
Dimethyl fumarate 410 vs. 408 DEFINE [34] 53% 0.17 vs. 0.36 41% 0.16 vs. 0.27
Dimethyl fumarate 359 vs. 363 CONFIRM [35] 44% 0.22 vs. 0.40 24% (N.S.) 0.13 vs. 0.17
Second-line
Fingolimod 425 vs. 418 FREEDOMS [38] 55% 0.18 vs. 0.40 28% 0.18 vs. 0.25
Fingolimod 358 vs. 355 FREEDOMS-2 [39] 48% 0.21 vs. 0.40 14% (N.S.) 0.25 vs. 0.29
Natalizumab 627 vs. 315 AFFIRM [41] 68% 0.23 vs. 0.73 42% 0.17 vs. 0.29
Mitoxantroneb 60 vs. 64 MIMS [54] 66% 0.35 vs. 1.02 64% 0.08 vs. 0.22
N, number of patients included in each treatment arm  note that the number only includes treatment arms with US Food and Drug Adminis-
tration/European Medicines Agency approved dosages; ARR, annualized relapse rate, active medication versus placebo; EDSS, Expanded Dis-
ability Status Scale; N.S., not signiﬁcant; i.m., intramuscular; s.c., subcutaneous. Disability progression is the proportion of patients with
3 months conﬁrmed progression in EDSS score, active medication versus placebo. a6 months conﬁrmed progression in EDSS score; bnot
approved in all European countries.
Table 2 Randomized controlled phase III clinical trials of the approved relapsingremitting multiple sclerosis medications, where the medica-
tions have been compared head-to-head with another active multiple sclerosis medication
Medication Compared to N
Trial name
(reference)
ARR Disability progression
Relative
reduction ARR
Relative
reduction
EDSS
progression
First-line
Interferon beta-1b Interferon beta-1a i.m. 92 vs. 96 INCOMIN [63] 24% 0.5 vs. 0.7 44% 0.13 vs. 0.30
Interferon-beta-1a
s.c.
Interferon-beta-1a i.m. 339 vs. 338 EVIDENCE [64] 16%a 0.54 vs. 0.64 13% (N.S.) 0.13 vs. 0.15
Interferon beta-1a
s.c.
Glatiramer acetate 386 vs. 378 REGARD [65] 3% (N.S) 0.30 vs. 0.29 25% (N.S.) 0.12 vs. 0.09
Interferon-beta-1b Glatiramer acetate 899 vs. 448 BEYOND [66] 3% (N.S) 0.33 vs. 0.34 5% (N.S.) 0.22 vs. 0.20
Teriﬂunomide Interferon-beta 1a s.c. 111 vs. 104 TENERE [31] 4% (N.S) 0.26 vs. 0.22 - -
Dimethyl fumarate Glatiramer acetate 359 vs. 350 CONFIRM [35] 24% (N.S) 0.22 vs. 0.29 17% (N.S.) 0.13 vs. 0.16
Second-line
Fingolimod Interferon beta-1a i.m. 431 vs. 435 TRANSFORMS
[40]
52%a 0.16 vs. 0.33 25% (N.S.) 0.06 vs. 0.08
Alemtuzumab Interferon beta-1a s.c. 376 vs. 202 CARE MS-1 [47] 55% 0.18 vs. 0.39 30% (N.S.) 0.08b vs. 0.11b
Alemtuzumab Interferon beta-1a s.c. 426 vs. 202 CARE MS-2 [48] 49% 0.26 vs. 0.52 42% 0.13b vs. 0.21b
N, number of patients included in each treatment arm  note that the number only includes treatment arms with US Food and Drug Adminis-
tration/European Medicines Agency approved dosages; ARR, annualized relapse rate during 2 years of follow-up, medication in column 1 ver-
sus medication in column 2; EDSS, Expanded Disability Status Scale; i.m., intramuscular; s.c., subcutaneous; N.S., not signiﬁcant. Disability
progression is the proportion of patients with 3 months conﬁrmed progression in EDSS score, medication in column 1 versus medication in
column 2. a1 year follow-up.; b6 months conﬁrmed progression in EDSS score.
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deﬁned by two or more disabling relapses in 1 year,
and with gadolinium-enhancing lesions on brain MRI
or a signiﬁcant increase in T2 lesion load compared to
a previous recent MRI. Careful risk stratiﬁcation for
potential adverse eﬀects is important, and most neu-
rologists would prefer ﬁngolimod or alemtuzumab for
patients who are JCV positive. Similarly, in the case
of contraindications for ﬁngolimod or alemtuzumab,
one of the other second-line treatment options should
be considered. The use of mitoxantrone has become
less frequent due to the relatively high risk of serious
side eﬀects, and may only be used in some cases of
SPMS. Stratiﬁcation for diﬀerences in clinical eﬀect is
diﬃcult due to the lack of treatment studies with
head-to-head comparisons of second-line therapies.
Some neurologists would prefer natalizumab for JCV-
negative patients due to the numerically higher reduc-
tion of ARR in pivotal trials, although treatment
eﬀect cannot be directly compared between diﬀerent
study populations.
For a small group of patients who do not respond
to the approved second-line treatments, oﬀ-label treat-
ments like rituximab [68] or ofatumumab [69] or
experimental therapy with autologous haematopoietic
stem cell transplantation [70] may be considered.
These treatment options have currently not been
tested in large phase III trials, but phase II trials or
case series reports have shown promising results.
These treatment options also seem to be eﬀective
against RRMS and not the progressive forms of the
disease [71].
Conclusions and future challenges
Although the last decade has shown a revolution in
treatment options for patients with MS, this has mainly
beneﬁted newly diagnosed patients with an RRMS dis-
ease course. None of the approved medications or
experimental therapies has shown convincing evidence
of slowing down or preventing disease progression in
patients with SPMS or PPMS. Thus there is an urgent
need to also improve the treatment options for patients
who have entered a progressive phase.
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